Halozyme Therapeutics (HALO) said Wednesday that Johnson & Johnson (JNJ) unit Janssen-Cilag International received European Commission approval for an indication extension of Darzalex co-formulated with Halozyme's Enhanze drug delivery technology to treat adults newly diagnosed with multiple myeloma.
The latest approval covers people with the disease regardless of transplant eligibility, Halozyme said.
Halozyme's Enhanze drug delivery technology is used for the subcutaneous delivery of injected drugs, the company said.
Halozyme shares were 1% lower in early trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。